Kolahi Sadeghi Leila, Vahidian Fatemeh, Eterafi Majid, Safarzadeh Elham
Cancer Immunology and Immunotherapy Research Center, Ardabil University of Medical Sciences, Ardabil, Iran.
Faculty of Medicine, Laval University, Quebec, Canada.
Infect Agent Cancer. 2024 Oct 5;19(1):50. doi: 10.1186/s13027-024-00605-3.
The most common illnesses that adversely influence human health globally are gastrointestinal malignancies. The prevalence of gastrointestinal cancers (GICs) is relatively high, and the majority of patients receive ineffective care since they are discovered at an advanced stage of the disease. A major component of the human body is thought to be the microbiota of the gastrointestinal tract and the genes that make up the microbiome. The gut microbiota includes more than 3000 diverse species and billions of microbes. Each of them has benefits and drawbacks and been demonstrated to alter anticancer medication efficacy. Treatment of GIC with the help of the gut bacteria is effective while changes in the gut microbiome which is linked to resistance immunotherapy or chemotherapy. Despite significant studies and findings in this field, more research on the interactions between microbiota and response to treatment in GIC are needed to help researchers provide more effective therapeutic strategies with fewer treatment complication. In this review, we examine the effect of the human microbiota on anti-cancer management, including chemotherapy, immunotherapy, and radiotherapy.
全球范围内对人类健康产生不利影响的最常见疾病是胃肠道恶性肿瘤。胃肠道癌症（GICs）的患病率相对较高，而且大多数患者由于在疾病晚期才被发现，因而接受的是无效治疗。胃肠道微生物群以及构成微生物组的基因被认为是人体的一个主要组成部分。肠道微生物群包括3000多种不同的物种和数十亿的微生物。它们每一种都有优缺点，并且已被证明会改变抗癌药物的疗效。借助肠道细菌治疗GIC是有效的，而肠道微生物组的变化与免疫治疗或化疗耐药性有关。尽管该领域有大量研究和发现，但仍需要对微生物群与GIC治疗反应之间的相互作用进行更多研究，以帮助研究人员提供更有效的治疗策略，减少治疗并发症。在这篇综述中，我们研究了人类微生物群对抗癌治疗（包括化疗、免疫治疗和放疗）的影响。
